Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 88

1.

Co-occurring alterations in the RAS-MAPK pathway limit response to MET inhibitor treatment in MET exon 14 skipping mutation-positive lung cancer.

Rotow JK, Gui P, Wu W, Raymond VM, Lanman RB, Kaye FJ, Peled N, Fece de la Cruz F, Nadres B, Corcoran RB, Yeh I, Bastian BC, Starostik P, Newsom K, Olivas V, Wolff AM, Fraser JS, Collisson EA, McCoach CE, Camidge DR, Pacheco J, Bazhenova L, Li T, Bivona TG, Blakely CM.

Clin Cancer Res. 2019 Sep 23. pii: clincanres.1667.2019. doi: 10.1158/1078-0432.CCR-19-1667. [Epub ahead of print]

PMID:
31548343
2.

Synthetic Essentiality of Metabolic Regulator PDHK1 in PTEN-Deficient Cells and Cancers.

Chatterjee N, Pazarentzos E, Mayekar MK, Gui P, Allegakoen DV, Hrustanovic G, Olivas V, Lin L, Verschueren E, Johnson JR, Hofree M, Yan JJ, Newton BW, Dollen JV, Earnshaw CH, Flanagan J, Chan E, Asthana S, Ideker T, Wu W, Suzuki J, Barad BA, Kirichok Y, Fraser JS, Weiss WA, Krogan NJ, Tulpule A, Sabnis AJ, Bivona TG.

Cell Rep. 2019 Aug 27;28(9):2317-2330.e8. doi: 10.1016/j.celrep.2019.07.063.

3.

Targeting Oncogenic BRAF: Past, Present, and Future.

Zaman A, Wu W, Bivona TG.

Cancers (Basel). 2019 Aug 16;11(8). pii: E1197. doi: 10.3390/cancers11081197. Review.

4.

CIC-DUX4 oncoprotein drives sarcoma metastasis and tumorigenesis via distinct regulatory programs.

Okimoto RA, Wu W, Nanjo S, Olivas V, Lin YK, Ponce RK, Oyama R, Kondo T, Bivona TG.

J Clin Invest. 2019 Jul 22;129(8):3401-3406. doi: 10.1172/JCI126366. eCollection 2019 Jul 22.

5.

Engineering Multidimensional Evolutionary Forces to Combat Cancer.

McCoach CE, Bivona TG.

Cancer Discov. 2019 May;9(5):587-604. doi: 10.1158/2159-8290.CD-18-1196. Epub 2019 Apr 16. Review.

PMID:
30992280
6.

Dampening oncogenic RAS signaling.

Bivona TG.

Science. 2019 Mar 22;363(6433):1280-1281. doi: 10.1126/science.aav6703. No abstract available.

PMID:
30898918
7.

Polytherapy and Targeted Cancer Drug Resistance.

Chatterjee N, Bivona TG.

Trends Cancer. 2019 Mar;5(3):170-182. doi: 10.1016/j.trecan.2019.02.003. Epub 2019 Feb 26. Review.

PMID:
30898264
8.

Emerging Targeted Therapies for the Treatment of Non-small Cell Lung Cancer.

Halliday PR, Blakely CM, Bivona TG.

Curr Oncol Rep. 2019 Feb 26;21(3):21. doi: 10.1007/s11912-019-0770-x. Review.

PMID:
30806814
9.

Principles of Resistance to Targeted Cancer Therapy: Lessons from Basic and Translational Cancer Biology.

Sabnis AJ, Bivona TG.

Trends Mol Med. 2019 Mar;25(3):185-197. doi: 10.1016/j.molmed.2018.12.009. Epub 2019 Jan 24. Review.

PMID:
30686761
10.

Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for PIK3CA-altered head and neck cancer.

Hedberg ML, Peyser ND, Bauman JE, Gooding WE, Li H, Bhola NE, Zhu TR, Zeng Y, Brand TM, Kim MO, Jordan RCK, VandenBerg S, Olivas V, Bivona TG, Chiosea SI, Wang L, Mills GB, Johnson JT, Duvvuri U, Ferris RL, Ha P, Johnson DE, Grandis JR.

J Exp Med. 2019 Feb 4;216(2):419-427. doi: 10.1084/jem.20181936. Epub 2019 Jan 25.

11.

Circulating tumor DNA analysis in patients with EGFR mutant lung cancer.

Nanjo S, Bivona TG.

J Thorac Dis. 2018 Nov;10(Suppl 33):S4061-S4064. doi: 10.21037/jtd.2018.09.106. No abstract available.

12.

Immunohistochemistry to Study YAP in Human Tissue Samples.

Haderk F, Olivas V, Bivona TG.

Methods Mol Biol. 2019;1893:89-95. doi: 10.1007/978-1-4939-8910-2_7.

PMID:
30565127
13.

Pathologic Complete Response to Neoadjuvant Crizotinib in a Lung Adenocarcinoma Patient With a MET Exon 14 Skipping Mutation.

Rotow JK, Woodard GA, Urisman A, McCoach CE, Bivona TG, Elicker BM, Jablons DM, Blakely CM.

Clin Lung Cancer. 2019 Mar;20(2):e137-e141. doi: 10.1016/j.cllc.2018.11.003. Epub 2018 Nov 20. No abstract available.

14.

Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins.

Neel DS, Allegakoen DV, Olivas V, Mayekar MK, Hemmati G, Chatterjee N, Blakely CM, McCoach CE, Rotow JK, Le A, Karachaliou N, Rosell R, Riess JW, Nichols R, Doebele RC, Bivona TG.

Cancer Res. 2019 Feb 1;79(3):546-556. doi: 10.1158/0008-5472.CAN-18-1492. Epub 2018 Dec 11.

PMID:
30538120
15.

Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer.

Shah KN, Bhatt R, Rotow J, Rohrberg J, Olivas V, Wang VE, Hemmati G, Martins MM, Maynard A, Kuhn J, Galeas J, Donnella HJ, Kaushik S, Ku A, Dumont S, Krings G, Haringsma HJ, Robillard L, Simmons AD, Harding TC, McCormick F, Goga A, Blakely CM, Bivona TG, Bandyopadhyay S.

Nat Med. 2019 Jan;25(1):111-118. doi: 10.1038/s41591-018-0264-7. Epub 2018 Nov 26.

16.

Cancer mutations and targeted drugs can disrupt dynamic signal encoding by the Ras-Erk pathway.

Bugaj LJ, Sabnis AJ, Mitchell A, Garbarino JE, Toettcher JE, Bivona TG, Lim WA.

Science. 2018 Aug 31;361(6405). pii: eaao3048. doi: 10.1126/science.aao3048.

17.

Compensatory increases of select proteostasis networks after Hsp70 inhibition in cancer cells.

Sannino S, Guerriero CJ, Sabnis AJ, Stolz DB, Wallace CT, Wipf P, Watkins SC, Bivona TG, Brodsky JL.

J Cell Sci. 2018 Sep 5;131(17). pii: jcs217760. doi: 10.1242/jcs.217760.

18.

RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.

Nichols RJ, Haderk F, Stahlhut C, Schulze CJ, Hemmati G, Wildes D, Tzitzilonis C, Mordec K, Marquez A, Romero J, Hsieh T, Zaman A, Olivas V, McCoach C, Blakely CM, Wang Z, Kiss G, Koltun ES, Gill AL, Singh M, Goldsmith MA, Smith JAM, Bivona TG.

Nat Cell Biol. 2018 Sep;20(9):1064-1073. doi: 10.1038/s41556-018-0169-1. Epub 2018 Aug 13.

19.

Emerging application of genomics-guided therapeutics in personalized lung cancer treatment.

Zaman A, Bivona TG.

Ann Transl Med. 2018 May;6(9):160. doi: 10.21037/atm.2018.05.02. Review.

20.

Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC.

Rolfo C, Mack PC, Scagliotti GV, Baas P, Barlesi F, Bivona TG, Herbst RS, Mok TS, Peled N, Pirker R, Raez LE, Reck M, Riess JW, Sequist LV, Shepherd FA, Sholl LM, Tan DSW, Wakelee HA, Wistuba II, Wynes MW, Carbone DP, Hirsch FR, Gandara DR.

J Thorac Oncol. 2018 Sep;13(9):1248-1268. doi: 10.1016/j.jtho.2018.05.030. Epub 2018 Jun 6. Review.

21.

The evolving understanding of immunoediting and the clinical impact of immune escape.

McCoach CE, Bivona TG.

J Thorac Dis. 2018 Mar;10(3):1248-1252. doi: 10.21037/jtd.2018.03.60. No abstract available.

22.

Oncogenic Signaling Pathways in The Cancer Genome Atlas.

Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, Dimitriadoy S, Liu DL, Kantheti HS, Saghafinia S, Chakravarty D, Daian F, Gao Q, Bailey MH, Liang WW, Foltz SM, Shmulevich I, Ding L, Heins Z, Ochoa A, Gross B, Gao J, Zhang H, Kundra R, Kandoth C, Bahceci I, Dervishi L, Dogrusoz U, Zhou W, Shen H, Laird PW, Way GP, Greene CS, Liang H, Xiao Y, Wang C, Iavarone A, Berger AH, Bivona TG, Lazar AJ, Hammer GD, Giordano T, Kwong LN, McArthur G, Huang C, Tward AD, Frederick MJ, McCormick F, Meyerson M; Cancer Genome Atlas Research Network, Van Allen EM, Cherniack AD, Ciriello G, Sander C, Schultz N.

Cell. 2018 Apr 5;173(2):321-337.e10. doi: 10.1016/j.cell.2018.03.035.

23.

TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer.

Gong K, Guo G, Gerber DE, Gao B, Peyton M, Huang C, Minna JD, Hatanpaa KJ, Kernstine K, Cai L, Xie Y, Zhu H, Fattah FJ, Zhang S, Takahashi M, Mukherjee B, Burma S, Dowell J, Dao K, Papadimitrakopoulou VA, Olivas V, Bivona TG, Zhao D, Habib AA.

J Clin Invest. 2018 Jun 1;128(6):2500-2518. doi: 10.1172/JCI96148. Epub 2018 May 7.

24.

Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-smallcell Lung Cancer Associated With Poor Prognosis.

Karachaliou N, Chaib I, Cardona AF, Berenguer J, Bracht JWP, Yang J, Cai X, Wang Z, Hu C, Drozdowskyj A, Servat CC, Servat JC, Ito M, Attili I, Aldeguer E, Capitan AG, Rodriguez J, Rojas L, Viteri S, Molina-Vila MA, Ou SI, Okada M, Mok TS, Bivona TG, Ono M, Cui J, Ramón Y Cajal S, Frias A, Cao P, Rosell R.

EBioMedicine. 2018 Mar;29:112-127. doi: 10.1016/j.ebiom.2018.02.001. Epub 2018 Feb 5.

25.

Non-Canonical Thinking for Targeting ALK-Fusion Onco-Proteins in Lung Cancer.

Wu W, Haderk F, Bivona TG.

Cancers (Basel). 2017 Nov 30;9(12). pii: E164. doi: 10.3390/cancers9120164. Review.

26.

Resistance is futile: overcoming resistance to targeted therapies in lung adenocarcinoma.

Neel DS, Bivona TG.

NPJ Precis Oncol. 2017;1. pii: 3. doi: 10.1038/s41698-017-0007-0. Epub 2017 Mar 20.

27.

Imaging PD-L1 Expression with ImmunoPET.

Truillet C, Oh HLJ, Yeo SP, Lee CY, Huynh LT, Wei J, Parker MFL, Blakely C, Sevillano N, Wang YH, Shen YS, Olivas V, Jami KM, Moroz A, Jego B, Jaumain E, Fong L, Craik CS, Chang AJ, Bivona TG, Wang CI, Evans MJ.

Bioconjug Chem. 2018 Jan 17;29(1):96-103. doi: 10.1021/acs.bioconjchem.7b00631. Epub 2017 Nov 15.

28.

Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers.

Blakely CM, Watkins TBK, Wu W, Gini B, Chabon JJ, McCoach CE, McGranahan N, Wilson GA, Birkbak NJ, Olivas VR, Rotow J, Maynard A, Wang V, Gubens MA, Banks KC, Lanman RB, Caulin AF, St John J, Cordero AR, Giannikopoulos P, Simmons AD, Mack PC, Gandara DR, Husain H, Doebele RC, Riess JW, Diehn M, Swanton C, Bivona TG.

Nat Genet. 2017 Dec;49(12):1693-1704. doi: 10.1038/ng.3990. Epub 2017 Nov 6.

29.

Understanding and targeting resistance mechanisms in NSCLC.

Rotow J, Bivona TG.

Nat Rev Cancer. 2017 Oct 25;17(11):637-658. doi: 10.1038/nrc.2017.84. Review.

PMID:
29068003
30.

Simultaneous evolutionary expansion and constraint of genomic heterogeneity in multifocal lung cancer.

Ma P, Fu Y, Cai MC, Yan Y, Jing Y, Zhang S, Chen M, Wu J, Shen Y, Zhu L, Chen HZ, Gao WQ, Wang M, Gu Z, Bivona TG, Zhao X, Zhuang G.

Nat Commun. 2017 Oct 10;8(1):823. doi: 10.1038/s41467-017-00963-0.

31.

Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer.

Jacobsen K, Bertran-Alamillo J, Molina MA, Teixidó C, Karachaliou N, Pedersen MH, Castellví J, Garzón M, Codony-Servat C, Codony-Servat J, Giménez-Capitán A, Drozdowskyj A, Viteri S, Larsen MR, Lassen U, Felip E, Bivona TG, Ditzel HJ, Rosell R.

Nat Commun. 2017 Sep 4;8(1):410. doi: 10.1038/s41467-017-00450-6.

32.

Current Landscape of Targeted Therapy in Lung Cancer.

Mayekar MK, Bivona TG.

Clin Pharmacol Ther. 2017 Nov;102(5):757-764. doi: 10.1002/cpt.810. Epub 2017 Sep 25. Review.

PMID:
28786099
33.

Activation of signal transducer and activator of transcription 3 (STAT3) signaling in EGFR mutant non-small-cell lung cancer (NSCLC).

Codony-Servat C, Codony-Servat J, Karachaliou N, Molina MA, Chaib I, Ramirez JL, de Los Llanos Gil M, Solca F, Bivona TG, Rosell R.

Oncotarget. 2017 Jul 18;8(29):47305-47316. doi: 10.18632/oncotarget.17625.

34.

A Case of Metastatic Atypical Neuroendocrine Tumor with ALK Translocation and Diffuse Brain Metastases.

Wang VE, Young L, Ali S, Miller VA, Urisman A, Wolfe J, Bivona TG, Damato B, Fogh S, Bergsland EK.

Oncologist. 2017 Jul;22(7):768-773. doi: 10.1634/theoncologist.2017-0054. Epub 2017 May 15.

35.

Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC.

Chaib I, Karachaliou N, Pilotto S, Codony Servat J, Cai X, Li X, Drozdowskyj A, Servat CC, Yang J, Hu C, Cardona AF, Vivanco GL, Vergnenegre A, Sanchez JM, Provencio M, de Marinis F, Passaro A, Carcereny E, Reguart N, Campelo CG, Teixido C, Sperduti I, Rodriguez S, Lazzari C, Verlicchi A, de Aguirre I, Queralt C, Wei J, Estrada R, Puig de la Bellacasa R, Ramirez JL, Jacobson K, Ditzel HJ, Santarpia M, Viteri S, Molina MA, Zhou C, Cao P, Ma PC, Bivona TG, Rosell R.

J Natl Cancer Inst. 2017 Sep 1;109(9). doi: 10.1093/jnci/djx014.

36.

Novel computational method for predicting polytherapy switching strategies to overcome tumor heterogeneity and evolution.

Jonsson VD, Blakely CM, Lin L, Asthana S, Matni N, Olivas V, Pazarentzos E, Gubens MA, Bastian BC, Taylor BS, Doyle JC, Bivona TG.

Sci Rep. 2017 Mar 13;7:44206. doi: 10.1038/srep44206.

37.

Dividing and conquering the variation among variants in EML4-ALK lung cancer.

Bivona TG.

Transl Cancer Res. 2017 Mar;6(Suppl 2):S369-S370. doi: 10.21037/tcr.2017.03.25. No abstract available.

38.

Superior Efficacy and Selectivity of Novel Small-Molecule Kinase Inhibitors of T790M-Mutant EGFR in Preclinical Models of Lung Cancer.

Rho JK, Lee IY, Choi YJ, Choi CM, Hur JY, Koh JS, Lee J, Suh BC, Song HJ, Salgaonkar P, Lee J, Lee J, Jung DS, Kim SY, Woo DC, Baek IJ, Lee JY, Ha CH, Sung YH, Kim JK, Kim WS, Song JS, Kim CH, Bivona TG, Lee JC.

Cancer Res. 2017 Mar 1;77(5):1200-1211. doi: 10.1158/0008-5472.CAN-16-2432. Epub 2017 Jan 12.

39.

Metastasis: From head to tail.

Okimoto RA, Bivona TG.

Cell Cycle. 2017 Mar 19;16(6):487-488. doi: 10.1080/15384101.2016.1271636. Epub 2017 Jan 5. No abstract available.

40.

Inactivation of Capicua drives cancer metastasis.

Okimoto RA, Breitenbuecher F, Olivas VR, Wu W, Gini B, Hofree M, Asthana S, Hrustanovic G, Flanagan J, Tulpule A, Blakely CM, Haringsma HJ, Simmons AD, Gowen K, Suh J, Miller VA, Ali S, Schuler M, Bivona TG.

Nat Genet. 2017 Jan;49(1):87-96. doi: 10.1038/ng.3728. Epub 2016 Nov 21.

41.

Transcriptomic-metabolomic reprogramming in EGFR-mutant NSCLC early adaptive drug escape linking TGFβ2-bioenergetics-mitochondrial priming.

Thiagarajan PS, Wu X, Zhang W, Shi I, Bagai R, Leahy P, Feng Y, Veigl M, Lindner D, Danielpour D, Yin L, Rosell R, Bivona TG, Zhang Z, Ma PC.

Oncotarget. 2016 Dec 13;7(50):82013-82027. doi: 10.18632/oncotarget.13307.

42.

Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.

Okimoto RA, Lin L, Olivas V, Chan E, Markegard E, Rymar A, Neel D, Chen X, Hemmati G, Bollag G, Bivona TG.

Proc Natl Acad Sci U S A. 2016 Nov 22;113(47):13456-13461. Epub 2016 Nov 9.

43.

HSP70 dependence in rhabdomyosarcoma: Seed or soil?

Sabnis AJ, Bivona TG.

Cell Cycle. 2017 Jan 17;16(2):147-148. doi: 10.1080/15384101.2016.1237168. Epub 2016 Sep 29. No abstract available.

44.

Combined chemical-genetic approach identifies cytosolic HSP70 dependence in rhabdomyosarcoma.

Sabnis AJ, Guerriero CJ, Olivas V, Sayana A, Shue J, Flanagan J, Asthana S, Paton AW, Paton JC, Gestwicki JE, Walter P, Weissman JS, Wipf P, Brodsky JL, Bivona TG.

Proc Natl Acad Sci U S A. 2016 Aug 9;113(32):9015-20. doi: 10.1073/pnas.1603883113. Epub 2016 Jul 22.

45.

Neoadjuvant Oncogene-Targeted Therapy in Early Stage Non-Small-Cell Lung Cancer as a Strategy to Improve Clinical Outcome and Identify Early Mechanisms of Resistance.

McCoach CE, Bivona TG, Blakely CM, Doebele RC.

Clin Lung Cancer. 2016 Sep;17(5):466-469. doi: 10.1016/j.cllc.2016.05.025. Epub 2016 Jun 8.

46.

An improved CTC isolation scheme for pairing with downstream genomics: Demonstrating clinical utility in metastatic prostate, lung and pancreatic cancer.

Premasekharan G, Gilbert E, Okimoto RA, Hamirani A, Lindquist KJ, Ngo VT, Roy R, Hough J, Edwards M, Paz R, Foye A, Sood R, Copren KA, Gubens M, Small EJ, Bivona TG, Collisson EA, Friedlander TW, Paris PL.

Cancer Lett. 2016 Sep 28;380(1):144-52. doi: 10.1016/j.canlet.2016.06.017. Epub 2016 Jun 22.

PMID:
27343980
47.

RAS-MAPK signaling influences the efficacy of ALK-targeting agents in lung cancer.

Hrustanovic G, Bivona TG.

Mol Cell Oncol. 2015 Oct 29;3(2):e1091061. doi: 10.1080/23723556.2015.1091061. eCollection 2016 Mar.

48.

The Hippo effector YAP regulates the response of cancer cells to MAPK pathway inhibitors.

Lin L, Bivona TG.

Mol Cell Oncol. 2015 Apr 27;3(1):e1021441. doi: 10.1080/23723556.2015.1021441. eCollection 2016 Jan.

49.

A framework for understanding and targeting residual disease in oncogene-driven solid cancers.

Bivona TG, Doebele RC.

Nat Med. 2016 May 5;22(5):472-8. doi: 10.1038/nm.4091.

50.

RAS signaling in ALK fusion lung cancer.

Hrustanovic G, Bivona TG.

Small GTPases. 2016;7(1):32-3. doi: 10.1080/21541248.2015.1131803. Epub 2016 Feb 22.

Supplemental Content

Loading ...
Support Center